Towards manufactured red blood cells for the treatment of inherited anemia.
Towards manufactured red blood cells for the treatment of inherited anemia.
复制标题
DOI:
10.3324/haematol.2020.268847
复制
发表时间:
2021-09-01
期刊:
影响因子:
10.1
通讯作者:
Toye AM
中科院分区:
文献类型:
--
作者:
Pellegrin S;Severn CE;Toye AM
Patients with inherited anemia and hemoglobinopathies (such as sickle cell disease and β-thalassemia) are treated with red blood cell (RBC) transfusions to alleviate their symptoms. Some of these patients may have rare blood group types or go on to develop alloimmune reactions, which can make it difficult to source compatible blood in the donor population. Laboratory-grown RBC represent a particularly attractive alternative which could satisfy an unmet clinical need. The challenge, however, is to produce - from a limited number of stem cells - the 2x1012 RBC required for a standard adult therapeutic dose. Encouraging progress has been made in RBC production from adult stem cells under good manufacturing practice. In 2011, the Douay group conducted a successful proof-of-principle mini-transfusion of autologous manufactured RBC in a single volunteer. In the UK, a trial is planned to assess whether manufactured RBC are equivalent to RBC produced naturally in donors, by testing an allogeneic mini-dose of laboratory-grown manufactured RBC in multiple volunteers. This review discusses recent progress in the erythroid culture field as well as opportunities for further scaling up of manufactured RBC production for transfusion practice.
登录
查看更多内容
影响因子:
10.1
作者:
Heideveld E;Hampton-O'Neil LA;Cross SJ;van Alphen FPJ;van den Biggelaar M;Toye AM;van den Akker E
通讯作者:
van den Akker E
影响因子:
4
作者:
Bernecker, Claudia;Ackermann, Mania;Dorn, Isabel
通讯作者:
Dorn, Isabel
影响因子:
2.9
作者:
COLLINS, AF;GONCALVESDIAS, C;OLIVIERI, NF
通讯作者:
OLIVIERI, NF
影响因子:
20.3
作者:
Huang, Nai-Jia;Lin, Ying-Cing;Lodish, Harvey
通讯作者:
Lodish, Harvey
影响因子:
7.5
作者:
Heshusius, Steven;Heideveld, Esther;van den Akker, Emile
通讯作者:
van den Akker, Emile